LifeSci Advisors provides companies in the life sciences industry with comprehensive solutions to communications and investor outreach. LifeSci Advisors increases client visibility within the investment community and educates investors on opportunities offered by these companies. Our core capabilities include non-deal roadshow planning and execution, KOL Events/R&D Days and financial communications. With a local presence in New York, Chicago, Boston, London, Geneva, Paris, and Tel-Aviv, LifeSci Advisors provides high quality service for clients with our intensive healthcare sector specialization. The LifeSci team has 350+ years of healthcare experience in sell-side research, institutional equity sales, capital markets/investment banking, institutional investing, VC investing and strategic IR advisory. We have long-standing relationships with key investors and senior professionals across the industry. Our healthcare expertise allows us to provide objective, unbiased advice to private and public biotech, specialty pharma, medical technology, diagnostics, and healthcare services companies.
BeiGene is a global, commercial-stage, research-based biotechnology company focused on molecularly-targeted and immuno-oncology cancer therapeutics. With a team of over 1,100 employees in China, the United States, and Australia, BeiGene is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. BeiGene is also working to create combination solutions aimed to have both a meaningful and lasting impact on cancer patients. BeiGene markets ABRAXANE® (nanoparticle albumin–bound paclitaxel), REVLIMID® (lenalidomide), and VIDAZA® (azaciditine) in China under a license from Celgene Corporation.
Bristol-Myers Squibb is a global biopharmaceutical company focused on discovering, developing and delivering innovative medicines for patients with serious diseases. Our medicines are helping millions of patients around the world in disease areas such as oncology, cardiovascular, immunoscience, fibrosis and others. We have built a sustainable pipeline of potential therapies, and are leveraging translational medicine and data analytics to understand how we can deliver the right medicine to the right patient at the right time to achieve the best outcome.
Through the Bristol-Myers Squibb Foundation, we also promote health equity and seek to improve health outcomes of populations disproportionately affected by serious diseases and conditions, giving new hope to some of the world’s most vulnerable people. Each day, our employees around the world work together for patients – it drives everything we do.
EIT Health is a network of best-in-class health innovators backed by the EU. We deliver solutions to enable European citizens to live longer, healthier lives by promoting innovation. We connect the right people and the right topics across European borders, so that innovation can happen at the intersection of research, education and business.
A global investment banking boutique serving companies in the life sciences industry. Since our inception in 2007, we have advised clients on more than $100 billion worth of deals for biotechnology, branded pharmaceutical, generic pharmaceutical, and life sciences companies. Our partners are senior industry bankers and executives, with deep experience, knowledge, and networks. We are a partner of choice for companies seeking discreet, conflict-free, and knowledgeable advice on M&A, pharmaceutical asset sale, capital markets, and licensing transactions. Torreya is differentiated from most other life sciences advisory practices by the breadth of its global presence. Over half the transactions on which we advise are cross-border. Torreya has offices in London, Mumbai, and New York, and affiliate offices on six continents.
Euronext is the leading pan-European exchange, covering Belgium, France, Ireland, The Netherlands, Norway, Portugal and the UK. With close to 1,500 listed issuers worth €4.5 trillion in market capitalisation as of end December 2019, Euronext has an unmatched blue chip franchise that includes 26 issuers in the Morningstar® Eurozone 50 Index℠ and a strong diverse domestic and international client base. Euronext operates regulated and transparent equity and derivatives markets and is the largest centre for debt and funds listings in the world. Its total product offering includes Equities, FX, Exchange Traded Funds, Warrants & Certificates, Bonds, Derivatives, Commodities and Indices. Euronext also leverages its expertise in running markets by providing technology and managed services to third parties. In addition to its main regulated market, Euronext also operates Euronext GrowthTM and Euronext AccessTM, simplifying access to listing for SMEs. The Norwegian stock exchange and its clearing & settlement subsidiary, together operating as Oslo Børs VPS, joined Euronext on 17 June 2019. For the latest news, find us on Twitter (twitter.com/euronext) and LinkedIn (linkedin.com/euronext).
BioMedPartners AG is a Basel-based Life Science Venture Capital Firm that invests in innovative private early- to mid-stage human Life Science companies in Switzerland and surrounding EU countries. It has recently raised a new fund, BioMedInvest-III LP, at CHF 100 million, and has now a total of CHF 350 million under management.